Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Feb 8;10(12):1230-1232.
doi: 10.18632/oncotarget.26652.

Abemaciclib: A multi-functional radiation modifier

Sarwat Naz  1 , John A Cook  1 , James B Mitchell  1
Affiliations
Editorial

Abemaciclib: A multi-functional radiation modifier

Sarwat Naz et al. Oncotarget. .
No abstract available

Keywords: CDK4/6 inhibitor; abemaciclib; radiation; radiosensitizer; vasculogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Abemaciclib, a selective CDK4/6 inhibitor with multiple actions
CDK4/6 inhibitors (Abemaciclib, Palbociclib and Ribociclib) are cell cycle blockers mainly at the G1/S border. In the presence of these inhibitors, CDK4/6-cyclinD complex formation is inhibited resulting in reduced phosphorylation of RB (Retinoblastoma) protein and release of E2F transcription factor inside the nucleus to drive cells in the replicative (S) phase of cell cycle. Some numerous potential targets within the tumor microenvironment (TME) whose modulation may lead to radiosensitisation on tumor cells by Abemaciclib is highlighted and described in the text. Prior to irradiation, tumor growth is governed largely by local angiogenesis. When local angiogenesis is inhibited by irradiation, growth of the tumor vasculature (essential for recurrence of the tumor) can occur from circulating cells, of which BMDCs (Bone Marrow Derived Cells) such as CD11b+ monocytes, myeloid cells and EPCs (Endothelial Progenitors Cells) are an essential component. After irradiation, the tumor becomes more hypoxic, and HIF-1 (Hypoxia Inducible Factor-1) is increased as the tumor attempts to regrow. This induces SDF-1 (Stroma Derived Factor-1) and promotes the mobilization of CD11b+ monocytes from the BM (Bone Marrow) and retention of these BMDCs into the tumor. SDF-1 is the key factor for the influx of BMDC. Abemaciclib, inhibits restoration of tumor vasculature post radiotherapy by inhibiting HIF-1 and SDF-1 expression in the tumor microenvironment.
See this image and copyright information in PMC

References

    1. Iwata H. Breast Cancer. 2018;25:402–406. - PubMed
    1. Klein ME, et al. Cancer Cell. 2018;34:9–20. - PMC - PubMed
    1. 2017 https://www.lilly.com
    1. Vijayaraghavan S, et al. Nat Commun. 2017;8:15916. - PMC - PubMed
    1. Ameratunga M, et al. Clin Cancer Research. 2019;25:21–28. - PubMed

Publication types

LinkOut - more resources